MedTrace Logo

Non-interventional Study on Time to Response and Quality of Life in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide in Second Line

NCT01430546 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 133

Last updated 2016-03-25

No results posted yet for this study

Summary

The purpose of this study is to quantify the burden of treatment in relapsed or refractory multiple myeloma in patients receiving lenalidomide after one prior treatment for myeloma.

Conditions

Sponsors & Collaborators

  • Hareth Nahi

    lead OTHER

Principal Investigators

  • Hareth Nahi, MD, PhD · Karolinska University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2016-01-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01430546 on ClinicalTrials.gov